{
  "id": 15019619,
  "title": "Forget Zepbound: 3 Newer Drugs That Could Power Eli Lilly's Next Leg Higher",
  "url": "https://urgent.news/2026/10/16/forget-zepbound-3-newer-drugs-that-could-power-eli-lillys-next-leg",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-10-16T18:38:00.000Z",
  "source": {
    "name": "Motley Fool",
    "slug": "motley-fool",
    "url": "https://www.fool.com/investing/2026/10/16/forget-zepbound-3-newer-drugs-that-could-power-eli/?source=iedfolrf0000001"
  },
  "original_language": "en",
  "account": "Eli Lilly's Zepbound, an anti-obesity medication, debuted in the U.S. in 2023 and has become a top seller in chronic weight management. However, the company has several other promising drugs that could fuel its future growth. Foundayo, an oral GLP-1 medicine approved for weight loss, has been gaining traction due to its convenience and potential label expansions, such as for diabetes and obstructive sleep apnea. Onswik, a once-weekly diabetes medicine, offers a more convenient regimen than daily insulin injections and could bolster Eli Lilly's diabetes portfolio. Retatrutide, an investigational weight-loss drug, mimics multiple gut hormones and has shown promising results in clinical trials, potentially becoming one of Eli Lilly's key growth drivers with its expected regulatory approval in early 2027.",
  "summary": "Eli Lilly's greatest strength isn't Zepbound. It is the company's drug discovery engine.",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 2,
    "also_reported_by": [
      {
        "outlet": "Nasdaq Markets",
        "title": "Forget Zepbound: 3 Newer Drugs That Could Power Eli Lilly's Next Leg Higher",
        "url": "https://urgent.news/2026/10/16/forget-zepbound-3-newer-drugs-that-could-power-eli-lillys-next-leg-15020622",
        "published": "2026-10-16T18:58:00.000Z"
      }
    ]
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}